ClinicalTrials.gg
RecruitingNCT06590896Updated Jun 3, 2025

Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures

A Phase 2 interventional study of Cenobamate in Epilepsies, Partial, sponsored by Ono Pharmaceutical Co. Ltd. Recruiting at 29 sites in Japan. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by Ono Pharmaceutical Co. Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Nov 2022, registered Aug 2024).
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Sex
All
01

Study summary

To evaluate the long-term safety and tolerability of cenobamate in Japanese epilepsy patients with partial seizures

02

Conditions studied

  • Epilepsies, Partial

Browse trials for

03

In context

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

This study's planned enrollment of 100 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.

Browse Epilepsies, Partial studies →

Lead sponsor

Ono Pharmaceutical Co. Ltd is the lead sponsor of 63 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects completed Study YKP3089C035 by SK Life Science.

Exclusion criteria

Exclusion Criteria:

  • Subjects that have previously discontinued for any reason from the Core study (YKP3089C035).
  • Any significant changes to the medical history of the subject that in the opinion of the investigator, could affect the safety of the subject.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Cenobamate

    Drug: Cenobamate

Interventions

  • Cenobamate will be orally administered once daily.

06

What researchers measure

Primary outcomes

  1. Incidences of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    The incidences of adverse events (AEs) and serious adverse events (SAEs) will be recorded.

    Time frame: Through study completion, an average of 4 years

  2. Urinalysis(pH)

    Measurement of urine pH.

    Time frame: Through study completion, an average of 4 years

  3. Urinalysis(Specific Gravity)

    Measurement of urine specific gravity (g/mL).

    Time frame: Through study completion, an average of 4 years

  4. Urinalysis(Protein)

    Measurement of urine protein (mg/dL).

    Time frame: Through study completion, an average of 4 years

  5. Urinalysis(Glucose)

    Measurement of urine glucose (mg/dL).

    Time frame: Through study completion, an average of 4 years

  6. Urinalysis(Ketone)

    Measurement of urine ketone (mg/dL).

    Time frame: Through study completion, an average of 4 years

  7. Urinalysis(Bilirubin)

    Measurement of urine bilirubin (mg/dL).

    Time frame: Through study completion, an average of 4 years

  8. Urinalysis(Blood)

    Measurement of urine blood (presence/absence).

    Time frame: Through study completion, an average of 4 years

  9. Urinalysis(Nitrite)

    Measurement of urine nitrite (presence/absence).

    Time frame: Through study completion, an average of 4 years

  10. Urinalysis(Urobilinogen)

    Measurement of urine urobilinogen (mg/dL).

    Time frame: Through study completion, an average of 4 years

  11. Urinalysis( Microscopic Examination)

    Microscopic examination of urine (if abnormal).

    Time frame: Through study completion, an average of 4 years

  12. Liver function tests(total protein)

    Measurement of total protein(g/dL)

    Time frame: Through study completion, an average of 4 years

  13. Liver function tests(albumin)

    Measurement of albumin(g/dL)

    Time frame: Through study completion, an average of 4 years

  14. Liver function tests(total bilirubin)

    Measurement of total bilirubin(mg/dL)

    Time frame: Through study completion, an average of 4 years

  15. Liver function tests(aspartate transaminase)

    Measurement of aspartate transaminase(U/L)

    Time frame: Through study completion, an average of 4 years

  16. Liver function tests(alanine aminotransferase)

    Measurement of alanine aminotransferase(U/L)

    Time frame: Through study completion, an average of 4 years

  17. Liver function tests(alkaline phosphatase)

    alkaline phosphatase(U/L)

    Time frame: Through study completion, an average of 4 years

  18. Liver function tests(gamma-glutamyl transferase)

    Measurement of gamma-glutamyl transferase(U/L)

    Time frame: Through study completion, an average of 4 years

  19. Hematology(Hemoglobin)

    Measurement of hemoglobin(g/dL)

    Time frame: Through study completion, an average of 4 years

  20. Hematology(hematocrit)

    Measurement of hematocrit(%)

    Time frame: Through study completion, an average of 4 years

  21. Hematology(white blood cell count)

    Measurement of white blood cell count(/μL)

    Time frame: Through study completion, an average of 4 years

  22. Hematology(red blood cell count)

    Measurement of red blood cell count(/μL)

    Time frame: Through study completion, an average of 4 years

  23. Hematology(mean corpuscular volume)

    Measurement of mean corpuscular volume(fL)

    Time frame: Through study completion, an average of 4 years

  24. Hematology(mean corpuscular hemoglobin)

    Measurement of mean corpuscular hemoglobin(pg)

    Time frame: Through study completion, an average of 4 years

  25. Hematology(red blood cell distribution width)

    Measurement of red blood cell distribution width(%)

    Time frame: Through study completion, an average of 4 years

  26. Hematology(platelet count)

    Measurement of platelet count(/μL)

    Time frame: Through study completion, an average of 4 years

  27. Serum chemistry(blood urea nitrogen)

    Measurement of blood urea nitrogen(mg/dL)

    Time frame: Through study completion, an average of 4 years

  28. Serum chemistry(calcium)

    Measurement of calcium(mg/dL)

    Time frame: Through study completion, an average of 4 years

  29. Serum chemistry(chloride)

    Measurement of chloride(mEq/L)

    Time frame: Through study completion, an average of 4 years

  30. Serum chemistry(creatinine)

    Measurement of creatinine(mg/dL)

    Time frame: Through study completion, an average of 4 years

  31. Serum chemistry(total bilirubin)

    Measurement of total bilirubin(mg/dL)

    Time frame: Through study completion, an average of 4 years

  32. Serum chemistry(direct bilirubin)

    Measurement of direct bilirubin(mg/dL)

    Time frame: Through study completion, an average of 4 years

  33. Serum chemistry(alkaline phosphatase)

    Measurement of alkaline phosphatas(U/L)

    Time frame: Through study completion, an average of 4 years

  34. Serum chemistry(alanine aminotransferase)

    Measurement of alanine aminotransferase(U/L)

    Time frame: Through study completion, an average of 4 years

  35. Serum chemistry(gamma-glutamyl transferase)

    Measurement of gamma-glutamyl transferase(U/L)

    Time frame: Through study completion, an average of 4 years

  36. Serum chemistry(total protein)

    Measurement of total protein(g/dL)

    Time frame: Through study completion, an average of 4 years

  37. Serum chemistry(albumin)

    Measurement of albumin(g/dL)

    Time frame: Through study completion, an average of 4 years

  38. Serum chemistry(globulin)

    Measurement of globulin(g/dL)

    Time frame: Through study completion, an average of 4 years

  39. Serum chemistry(sodium)

    Measurement of sodium(mEq/L)

    Time frame: Through study completion, an average of 4 years

  40. Serum chemistry(potassium)

    Measurement of potassium(mEq/L)

    Time frame: Through study completion, an average of 4 years

  41. Serum chemistry(phosphorus)

    Measurement of phosphorus(mq/dL)

    Time frame: Through study completion, an average of 4 years

  42. Serum chemistry(glucose)

    Measurement of glucose(mq/dL)

    Time frame: Through study completion, an average of 4 years

  43. Heart rate

    heart rate (beats per minute)

    Time frame: Through study completion, an average of 4 years

  44. Respiratory Rate

    Respiratory Rate (breaths per minute),

    Time frame: Through study completion, an average of 4 years

  45. Blood Pressure

    blood pressure, both of systolic and diastolic (mm Hg)

    Time frame: Through study completion, an average of 4 years

  46. Electrocardiogram (ECG) Findings

    ECG findings, including heart rate (beats per minute), PR Interval (milliseconds), PQ Interval (milliseconds), RR Interval (milliseconds), QRS Interval (milliseconds), and QT Interval (milliseconds), will be recorded.

    Time frame: Through study completion, an average of 4 years

  47. Columbia-Suicide Severity Rating Scale (C-SSRS) Scores

    Scores on the Columbia-Suicide Severity Rating Scale (C-SSRS) will be recorded. Questions regarding suicide are recorded as yes or no, and the percentage of subject with suicide risk (yes) is assessed.

    Time frame: Through study completion, an average of 4 years

Secondary outcomes

  1. Percentage Change in all partial seizure frequency per 28-Day

    It will confirm the frequency of partial seizures at 28-day intervals and calculate the percentage change until the study is completed.

    Time frame: Through study completion, an average of 4 years

07

Study locations

29 of 29 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Jan 2027, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2024
First posted
Sep 19, 2024
StartActual
Nov 4, 2022
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2027
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06590896
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Nov 4, 2022
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Jun 3, 2025

Study contacts

North America Clinical Trial Support Desk
Contact
clinical_trial@ono-pharma.com
+18665877745(Toll-Free)
International Clinical Trial Support Desk
Contact
clinical_trial@ono-pharma.com
+17162141777(Standard)
Project Leader
study director · Ono Pharmaceutical Co. Ltd

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cenobamate

Start the discussion